Markus A Schirmer1, Julia Beck2, Martin Leu3, Michael Oellerich4, Margret Rave-Fränk3, Philip D Walson4, Ekkehard Schütz2, Martin Canis5. 1. Clinic of Radiotherapy and Radiation Oncology, University Medical Center Göttingen, Göttingen, Germany; mschirmer@med.uni-goettingen.de. 2. Chronix Biomedical, Göttingen, Germany. 3. Clinic of Radiotherapy and Radiation Oncology, University Medical Center Göttingen, Göttingen, Germany. 4. Institute of Clinical Pharmacology, University Medical Center Göttingen, Germany. 5. Clinic of Otorhinolaryngology, Ludwig-Maximilian University of Munich, Germany.
Abstract
BACKGROUND: Clinicians face many challenges in disease stratification and outcome prediction in head and neck squamous cancer cell (HNSCC) patients. Given the limitations of currently used clinical scoring, repetitive biopsies, and imaging techniques, liquid biopsy approaches may provide valuable additional diagnostic and prognostic information. METHODS: A noninterventional, single-center observational study was performed with clinical data and plasma samples from HNSCC patients. Cell-free tumor DNA-derived copy number aberrations (CNAs) were determined in 116 patients by low-coverage next-generation sequencing (NGS). Significant CNAs were combined in a genome-wide copy number instability score (CNI), which was evaluated with respect to conventional clinical staging and patient outcome. RESULTS: Receiver-operating characteristic (ROC) curve analysis comparing the presurgery CNI in patients (n = 103) with that in tumor-free controls (n = 142) yielded an area under the ROC curve of 87.2% (95% CI, 79.4%-93.3%). At a specificity of 95%, the sensitivity to detect tumors varied between 46% (pT1) and 94% (pT4). A CNI above the median (i.e., >72) had a positive predictive value of 90% (95% CI, 79%-96%) for lymph node involvement (LNI), while the negative predictive value was 57% (95% CI, 43%-70%). For a CNI >72, overall survival (OS) was worse (hazard ratio, 4.89; 95% CI, 1.39-17.17; P = 0.01) with 62% and 90% survivors 3 years after surgery for a CNI >72 and ≤72, respectively. In multivariable models, the CNI was a superior predictor of OS compared to established disease features, including LNI. CONCLUSIONS: The CNI may assist in predicting LNI and prognosis in HNSCC with direct therapeutic implications concerning the need for neck dissection or more aggressive treatment.
BACKGROUND: Clinicians face many challenges in disease stratification and outcome prediction in head and neck squamous cancer cell (HNSCC) patients. Given the limitations of currently used clinical scoring, repetitive biopsies, and imaging techniques, liquid biopsy approaches may provide valuable additional diagnostic and prognostic information. METHODS: A noninterventional, single-center observational study was performed with clinical data and plasma samples from HNSCC patients. Cell-free tumor DNA-derived copy number aberrations (CNAs) were determined in 116 patients by low-coverage next-generation sequencing (NGS). Significant CNAs were combined in a genome-wide copy number instability score (CNI), which was evaluated with respect to conventional clinical staging and patient outcome. RESULTS: Receiver-operating characteristic (ROC) curve analysis comparing the presurgery CNI in patients (n = 103) with that in tumor-free controls (n = 142) yielded an area under the ROC curve of 87.2% (95% CI, 79.4%-93.3%). At a specificity of 95%, the sensitivity to detect tumors varied between 46% (pT1) and 94% (pT4). A CNI above the median (i.e., >72) had a positive predictive value of 90% (95% CI, 79%-96%) for lymph node involvement (LNI), while the negative predictive value was 57% (95% CI, 43%-70%). For a CNI >72, overall survival (OS) was worse (hazard ratio, 4.89; 95% CI, 1.39-17.17; P = 0.01) with 62% and 90% survivors 3 years after surgery for a CNI >72 and ≤72, respectively. In multivariable models, the CNI was a superior predictor of OS compared to established disease features, including LNI. CONCLUSIONS: The CNI may assist in predicting LNI and prognosis in HNSCC with direct therapeutic implications concerning the need for neck dissection or more aggressive treatment.
Authors: Vasudha Mishra; Alka Singh; Xiangying Chen; Ari J Rosenberg; Alexander T Pearson; Alex Zhavoronkov; Peter A Savage; Mark W Lingen; Nishant Agrawal; Evgeny Izumchenko Journal: Br J Cancer Date: 2021-12-07 Impact factor: 7.640
Authors: Susanne Flach; Karen Howarth; Sophie Hackinger; Christodoulos Pipinikas; Pete Ellis; Kirsten McLay; Giovanni Marsico; Tim Forshew; Christoph Walz; Christoph A Reichel; Olivier Gires; Martin Canis; Philipp Baumeister Journal: Br J Cancer Date: 2022-02-07 Impact factor: 9.075
Authors: Elena Ioana Braicu; Andreas du Bois; Jalid Sehouli; Julia Beck; Sonia Prader; Hagen Kulbe; Bernd Eiben; Philipp Harter; Alexander Traut; Klaus Pietzner; Ralf Glaubitz; Beyhan Ataseven; Radoslav Chekerov; Christoph Keck; Thomas Winkler; Sebastian Heikaus; Peggy Gellendin; Ekkehard Schütz; Florian Heitz Journal: Cancers (Basel) Date: 2021-12-30 Impact factor: 6.639
Authors: Araceli Diez-Fraile; Joke De Ceulaer; Charlotte Derpoorter; Christophe Spaas; Tom De Backer; Philippe Lamoral; Johan Abeloos; Tim Lammens Journal: Int J Mol Sci Date: 2022-02-22 Impact factor: 5.923